CF
MRNS

Cantor Fitzgerald’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Cantor Fitzgerald’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62,520
Closed -$679K – 650
2023
Q2 		$679K Buy
+62,520
New +$535K 0.02% 334

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Cantor Fitzgerald's MRNS Position: Q3 2023 in Review

Cantor Fitzgerald sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 62,520 shares — an estimated $679K sold.

Cantor Fitzgerald first reported a position in MRNS in Q2 2023 and held it in 1 quarter. The position peaked at $679K in Q2 2023. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

  • Cantor Fitzgerald reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 62,520 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $679K.
  • Cantor Fitzgerald first reported a position in Marinus Pharmaceuticals, Inc in Q2 2023 and held it in 1 quarter.
  • Cantor Fitzgerald's Marinus Pharmaceuticals, Inc position peaked at $679K in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Cantor Fitzgerald's 13F filing for Q3 2023, filed 14 Nov 2023.